For research use only. Not for therapeutic Use.
RETRA is a mutant p53-dependent activator of p73 that suppresses mutant p53-bearing cancer cells. RETRA increases the expression level of p73, and a release of p73 from the blocking complex with mutant p53, which produces tumor-suppressor effects[1].
Catalog Number | I011715 |
CAS Number | 1036069-26-7 |
Synonyms | 2-(4,5-dihydro-1,3-thiazol-2-ylsulfanyl)-1-(3,4-dihydroxyphenyl)ethanone |
Molecular Formula | C11H11NO3S2 |
Purity | ≥95% |
InChI | InChI=1S/C11H11NO3S2/c13-8-2-1-7(5-9(8)14)10(15)6-17-11-12-3-4-16-11/h1-2,5,13-14H,3-4,6H2 |
InChIKey | OHNNJGHRUIGGBO-UHFFFAOYSA-N |
SMILES | C1CSC(=N1)SCC(=O)C2=CC(=C(C=C2)O)O |
Reference | [1]. J E Kravchenko, et al. Small-molecule RETRA suppresses mutant p53-bearing cancer cells through a p73-dependent salvage pathway. Proc Natl Acad Sci U S A. 2008 Apr 29;105(17):6302-7. |